InvestorsHub Logo
Followers 8
Posts 598
Boards Moderated 0
Alias Born 05/06/2020

Re: Jeff Taitano post# 86699

Friday, 03/12/2021 9:20:33 AM

Friday, March 12, 2021 9:20:33 AM

Post# of 199217
There is definitely an ongoing dust up between Dimitar and Harry. You can also check the Immunotech BG Facebook page. Dimitar is clearly not happy.

As to what you quote from the filings:

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.



The problem is that there was never any follow on filing indicating the purchase agreement actually came to fruition. But assuming it did come to fruition, then $IMMB holds some number of shares in $ENZC and a note receivable. Stock paid directly to Dimitar or others with Bulgarian names is different than stock that would belong to the shareholders of $IMMB common stock, so it's hard to characterize $IMMB as a dead ticker since it clearly owns something, whether it be IP and 49% interest in Immunotech BG, or a note receivable and $ENZC common stock. Unfortunately, there is an incomplete accounting of this deal if it did, in fact, go through and this is complicated by Harry serving as CEO of $IMMB and CSO of $ENZC at the same time.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENZC News